Contribution: Industrial Research Assistance Program – Contributions to Firms
Dalriada Drug Discovery Inc.
$500,000.00
E!7296 COVANEXT: Unlocking druggability of disordered proteins
EF 2025-26 · 2025-04-01
Résumé
E!7296 COVANEXT: Unlocking druggability of disordered proteins
Co-International partner: Nuage Therapeutics SL, Spain
To advance the development of NT-A, a first-in-class covalent therapeutic for small cell lung cancer (SCLC).
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Mississauga|Mississauga, Ontario, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
716905096
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Agreement End Date
2027-03-30
Agreement Number
1028974
Agreement Start Date
2025-04-01
Agreement Title
E!7296 COVANEXT: Unlocking druggability of disordered proteins
Agreement Title (French)
E!7296 COVANEXT : Débloquer la possibilité de traiter les protéines désordonnées
Agreement Type
Contribution
Agreement Value
$500,000.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
E!7296 COVANEXT: Unlocking druggability of disordered proteins
Co-International partner: Nuage Therapeutics SL, Spain
To advance the development of NT-A, a first-in-class covalent therapeutic for small cell lung cancer (SCLC).
Description (French)
E!7296 COVANEXT : Débloquer la possibilité de traiter les protéines désordonnées Partenaire co-international : Nuage Therapeutics SL, Espagne Faire progresser le développement de NT-A, un traitement thérapeutique covalent de première classe pour le cancer du poumon à petites cellules (SCLC).
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Mississauga--Streetsville
Federal Riding (French)
Mississauga--Streetsville
Federal Riding Number
35063
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
716905096
Recipient City
Mississauga|Mississauga
Recipient Country
CA
Recipient Legal Name
Dalriada Drug Discovery Inc.
Recipient Operating Name
Dalriada
Recipient Postal Code
L5N 8G4
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2025-2026-Q1-1028974
